In an effort to establish more sustainable and consistent growth in revenues and earnings, The Female Health Company (FHCO -10.9%) initiates several initiatives to support its growth strategy.
President & CEO Karen King hires Susan Ostrowski as EVP of New Business Development responsible for the company's sales, marketing and sales support functions. Ms. Ostrowski will lead the commercialization efforts for the FC2 Female Condom.
The BOD approves the suspension of the quarterly dividend. The funds will be redirected to growing the market for the FC2, investing in new products, technologies and/or businesses that complement FHCO's current business and to buy back shares.
FHCO will report Q2 results on July 31. It expects to report sales of ~13.7M FC2 units.